Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Inventory (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Inventory data on record, last reported at $24.9 million in Q4 2025.

  • For Q4 2025, Inventory rose 11.09% year-over-year to $24.9 million; the TTM value through Dec 2025 reached $24.9 million, up 11.09%, while the annual FY2025 figure was $24.9 million, 11.09% up from the prior year.
  • Inventory reached $24.9 million in Q4 2025 per MIRM's latest filing, up from $24.0 million in the prior quarter.
  • Across five years, Inventory topped out at $24.9 million in Q4 2025 and bottomed at $1.5 million in Q4 2021.
  • Average Inventory over 5 years is $14.4 million, with a median of $21.6 million recorded in 2024.
  • Peak YoY movement for Inventory: soared 318.54% in 2023, then increased 0.41% in 2024.
  • A 5-year view of Inventory shows it stood at $1.5 million in 2021, then soared by 267.81% to $5.6 million in 2022, then soared by 300.93% to $22.3 million in 2023, then rose by 0.41% to $22.4 million in 2024, then grew by 11.09% to $24.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $24.9 million in Q4 2025, $24.0 million in Q3 2025, and $22.9 million in Q2 2025.